---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294418335.md"
description: "Several healthcare stocks moved significantly in Thursday's after-market session, largely driven by Q2 earnings reports. Gainers included Scribe Therapeutics (+12.7%), uniQure (+9.5%), Guardant Health (+8.3%), CareDx (+7.6%), Castle Biosciences (+7.6%), and Healthcare Triangle (+7.4%). Conversely, major losers were Karyopharm Therapeutics (-59.1%), Myriad Genetics (-30.6%), Nuwellis (-29.0%), Fulgent Genetics (-16.9%), Alignment Healthcare (-14.3%), and Cerus (-13.9%)."
datetime: "2026-07-30T21:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294418335.md)
  - [en](https://longbridge.com/en/news/294418335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294418335.md)
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Scribe Therapeutics** (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million.
-   **uniQure** (NASDAQ:QURE) shares increased by 9.5% to $46.2. The company's market cap stands at $2.7 billion. As per the press release, Q2 earnings came out yesterday.
-   **Guardant Health** (NASDAQ:GH) shares moved upwards by 8.3% to $165.0. The market value of their outstanding shares is at $19.1 billion. As per the press release, Q2 earnings came out today.
-   **CareDx** (NASDAQ:CDNA) shares increased by 7.61% to $41.0. The company's market cap stands at $1.8 billion. The company's, Q2 earnings came out today.
-   **Castle Biosciences** (NASDAQ:CSTL) shares moved upwards by 7.61% to $28.83. The company's market cap stands at $741.0 million. As per the news, the Q2 earnings report came out today.
-   **Healthcare Triangle** (NASDAQ:HCTI) shares moved upwards by 7.42% to $1.23. The company's market cap stands at $3.1 million.

### Losers

-   **Karyopharm Therapeutics** (NASDAQ:KPTI) stock fell 59.1% to $2.87 during Thursday's after-market session. The company's market cap stands at $155.4 million.
-   **Myriad Genetics** (NASDAQ:MYGN) shares fell 30.57% to $3.73. The market value of their outstanding shares is at $476.0 million. As per the press release, Q2 earnings came out today.
-   **Nuwellis** (NASDAQ:NUWE) shares decreased by 28.98% to $3.16.
-   **Fulgent Genetics** (NASDAQ:FLGT) shares decreased by 16.87% to $16.8. The market value of their outstanding shares is at $607.1 million. As per the news, the Q2 earnings report came out today.
-   **Alignment Healthcare** (NASDAQ:ALHC) stock decreased by 14.3% to $15.95. The company's market cap stands at $3.7 billion. The company's, Q2 earnings came out today.
-   **Cerus** (NASDAQ:CERS) stock decreased by 13.85% to $2.49. The market value of their outstanding shares is at $575.0 million. As per the press release, Q2 earnings came out today. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md)
- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [GH.US](https://longbridge.com/en/quote/GH.US.md)
- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)
- [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md)
- [FLGT.US](https://longbridge.com/en/quote/FLGT.US.md)
- [HCTI.US](https://longbridge.com/en/quote/HCTI.US.md)
- [CSTL.US](https://longbridge.com/en/quote/CSTL.US.md)
- [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md)
- [ALHC.US](https://longbridge.com/en/quote/ALHC.US.md)
- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

- [How Investors Are Reacting To Guardant Health (GH) Spotlighting Shield Test And Teeing Up Earnings](https://longbridge.com/en/news/294426643.md)
- [CareDx Q2 revenue beats estimates; outlook lifted](https://longbridge.com/en/news/294409121.md)
- [Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint](https://longbridge.com/en/news/294410278.md)
- [Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay](https://longbridge.com/en/news/294410077.md)
- [Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating](https://longbridge.com/en/news/294446991.md)